Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

V. Brodszky, P. Baji, O. Balogh, M. Péntek

Research output: Contribution to journalArticle (Academic Journal)peer-review

106 Citations (Scopus)

Cite this